What's Happening?
Infectious disease experts worldwide are raising alarms over a growing resistance to antifungal drugs, which they describe as a 'silent surge.' This resistance is particularly concerning with pathogens like Candida auris and azole-resistant Aspergillus,
which are increasingly found in intensive care units and communities. The experts, led by Paul Verweij from Radboud University Medical Centre, have published a five-step plan in Nature Medicine to address this issue. Their plan aims to influence the World Health Organization's upcoming update to its Global Action Plan on Antimicrobial Resistance (AMR). The proposed measures include raising awareness, improving surveillance, enhancing infection prevention and control, optimizing current antifungal therapies, and increasing investment in new diagnostics and medicines. The experts emphasize the need for support in low- and middle-income countries, where the impact of drug-resistant fungi is particularly severe.
Why It's Important?
The rise in antifungal drug resistance poses a significant threat to global health, as invasive fungal diseases already affect over 6.5 million people annually, with high mortality rates. The resistance exacerbates the challenge of treating these infections, which are particularly dangerous for immunocompromised individuals. The experts warn that without integrating antifungal resistance into global AMR strategies, the world risks repeating past mistakes made with antibacterial resistance. This situation could lead to increased healthcare costs, longer hospital stays, and higher mortality rates. The call for action highlights the need for a coordinated global response to prevent a potential public health crisis.
What's Next?
The experts hope their recommendations will be incorporated into the WHO's updated Global Action Plan on AMR, expected later this year. They advocate for concrete milestones and funding to support the plan's implementation. The focus will be on developing new antifungal agents and improving existing treatments. Additionally, there is a call for equitable financing and stewardship that integrates clinical, agricultural, and environmental policies. The pharmaceutical industry's retreat from developing new antifungal drugs has left a gap that needs addressing to prevent further resistance development.
Beyond the Headlines
The dual use of antifungal agents in medicine and agriculture is accelerating resistance, as highlighted by Professor Michaela Lackner. This cross-sectoral issue requires integrated policies to manage resistance effectively. The lack of new antifungal drugs entering the market underscores the need for innovation and investment in this area. The experts' call to action serves as a reminder of the interconnectedness of human, animal, and environmental health, emphasizing the importance of a One Health approach to tackle antimicrobial resistance.
